EP1593738A4 - Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier - Google Patents

Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier

Info

Publication number
EP1593738A4
EP1593738A4 EP04706596A EP04706596A EP1593738A4 EP 1593738 A4 EP1593738 A4 EP 1593738A4 EP 04706596 A EP04706596 A EP 04706596A EP 04706596 A EP04706596 A EP 04706596A EP 1593738 A4 EP1593738 A4 EP 1593738A4
Authority
EP
European Patent Office
Prior art keywords
virus
dengue virus
carrier
antigen
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04706596A
Other languages
German (de)
French (fr)
Other versions
EP1593738A1 (en
Inventor
Xiaowu Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TENGEN BIOMEDICAL Co
Original Assignee
TENGEN BIOMEDICAL Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TENGEN BIOMEDICAL Co filed Critical TENGEN BIOMEDICAL Co
Publication of EP1593738A1 publication Critical patent/EP1593738A1/en
Publication of EP1593738A4 publication Critical patent/EP1593738A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types can be used to repeatedly produce efficient immune response, which strengthen body's immune response against the pathogen containing such antigen. Such vaccine can prevent and cure cancer and viral diseases.
EP04706596A 2003-01-30 2004-01-30 Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier Withdrawn EP1593738A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN03115272 2003-01-30
CN03115272 2003-01-30
CN03115273 2003-01-30
CN03115273 2003-01-30
PCT/CN2004/000088 WO2004072274A1 (en) 2003-01-30 2004-01-30 Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier

Publications (2)

Publication Number Publication Date
EP1593738A1 EP1593738A1 (en) 2005-11-09
EP1593738A4 true EP1593738A4 (en) 2006-05-31

Family

ID=32870114

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04706596A Withdrawn EP1593738A4 (en) 2003-01-30 2004-01-30 Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier

Country Status (3)

Country Link
US (3) US20060018928A1 (en)
EP (1) EP1593738A4 (en)
WO (1) WO2004072274A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986686A4 (en) * 2006-02-13 2010-08-11 Integral Molecular Inc A dengue reporter virus and methods of making and using the same
EP1991709B1 (en) 2006-02-27 2017-01-25 The Board of Regents of The University of Texas System Pseudoinfectious flavivirus and uses thereof
EP2571990A4 (en) * 2010-05-21 2013-11-20 Univ Pittsburgh Universal dengue virus sequences and methods of use
US8685649B2 (en) 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
CA3045650A1 (en) * 2016-12-05 2018-06-14 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
CN113604483A (en) * 2021-07-13 2021-11-05 中山大学 Dengue virus serum 3-type epidemic strain GZ14D3 replicon and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072803A2 (en) * 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
WO2003046189A1 (en) * 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
JP2002500003A (en) * 1997-11-28 2002-01-08 ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス Flavivirus expression and delivery systems
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072803A2 (en) * 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
WO2003046189A1 (en) * 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANRAKU ITARU ET AL: "Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity", JOURNAL OF VIROLOGY, vol. 76, no. 8, April 2002 (2002-04-01), pages 3791 - 3799, XP002374739, ISSN: 0022-538X *
KHROMYKH A A: "REPLICON-BASED VECTORS OF POSITIVE STRAND RNA VIRUSES", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 5, 2000, pages 555 - 569, XP008006752, ISSN: 1464-8431 *
PANG X ET AL: "Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: A potential future tool for dual vaccination against dengue virus and HIV", BMC MICROBIOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 1, no. 28, 13 November 2001 (2001-11-13), pages 1 - 9, XP002244012, ISSN: 1471-2180 *
See also references of WO2004072274A1 *
VARNAVSKI A N ET AL: "Noncytopathic Flavivirus Replicon RNA-Based System for Expression and Delivery of Heterologous Genes", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 255, no. 2, 15 March 1999 (1999-03-15), pages 366 - 375, XP004440024, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
US20090197319A1 (en) 2009-08-06
US20090149405A1 (en) 2009-06-11
EP1593738A1 (en) 2005-11-09
WO2004072274A1 (en) 2004-08-26
US20060018928A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
HK1067058A1 (en) Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
SG149870A1 (en) Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
EP1504112A4 (en) Development of a preventive vaccine for filovirus infection in primates
WO2008011609A3 (en) Compositions and methods for vaccinating against hsv-2
WO2006074303A3 (en) Delivery vehicles, bioactive substances and viral vaccines
EP2292097A3 (en) Recombinant parainfluenza virus expression systems and vaccines
WO2021154812A8 (en) Coronavirus vaccine formulations
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2009080715A3 (en) Vaccines for malaria
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP1593738A4 (en) Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
WO2007046839A3 (en) New live virus vaccines
DE69533067D1 (en) HEPATIS E-VIRUS ANTIGENE AND THEIR USE
EP1439856A4 (en) Recombinant rabies vaccine and methods of preparation and use
MXPA02012593A (en) Bvdv virus-like particles.
EP1427443A4 (en) Vaccine using papilloma virus e proteins delivered by viral vector
WO2023102448A3 (en) Coronavirus vaccine formulations
ATE505482T1 (en) VACCINE AGAINST INFECTIOUS SALMON ANEMIA VIRUS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/18 20060101ALI20060401BHEP

Ipc: C12N 15/40 20060101ALI20060401BHEP

Ipc: C12N 15/86 20060101ALI20060401BHEP

Ipc: A61K 39/12 20060101ALI20060401BHEP

Ipc: C12N 7/04 20060101AFI20040901BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060418

17Q First examination report despatched

Effective date: 20070608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100225